Seagen touts full PhII Tukysa da­ta as it plots col­orec­tal can­cer ex­pan­sion

As ru­mors of a Mer­ck buy­out con­tin­ue to swirl around Seagen, the big Seat­tle biotech is charg­ing ahead with new da­ta for its can­cer drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.